药物与认知行为疗法治疗疑病症的随机对照试验
这项随机对照试验纳入195例DSM-IV疑病症患者,比较安慰剂、CBT、氟西汀及联合治疗。第24周联合治疗应答率47.2%,单药活性治疗41.8%,安慰剂29.6%,趋势检验显著;但各活性治疗与安慰剂应答率差异无统计学意义。氟西汀在Whiteley指数连续测量上显著优于安慰剂,联合治疗有少量增量效益。
要点
- 联合治疗应答率47.2%高于单药活性治疗41.8%和安慰剂29.6%,趋势检验显著。
- 各活性治疗与安慰剂的应答率差异无统计学意义。
- 氟西汀在Whiteley指数连续测量上显著优于安慰剂,CBT未显示显著优势。
核心结论
- 本研究支持氟西汀治疗疑病症的安全性、耐受性和有效性,联合治疗提供少量增量效益,但约50%患者未应答,需要新的或更强化的方法。
研究设计与样本
- 随机对照试验,195例DSM-IV疑病症患者随机分配至安慰剂、CBT、氟西汀或氟西汀联合CBT四组,主要分析第24周意向治疗样本的应答情况。
主要发现
- 应答率:联合治疗组47.2%,单药活性治疗组41.8%,安慰剂组29.6%,趋势检验假设模式(联合>单药>安慰剂)显著。
- 各活性治疗与安慰剂的应答率差异无统计学意义。
- Whiteley指数连续测量显示,氟西汀(而非CBT)在第24周显著优于安慰剂,且24周内改善速度显著更快。
- 氟西汀较安慰剂显著减少焦虑并改善生活质量。
- 脱落率组间无差异,治疗中出现的不良事件分布均匀。
关键数值与推荐
- 应答定义为Whiteley指数和疑病症改良版Yale-Brown强迫量表(H-YBOCS-M)均较基线改善≥25%。
- 主要分析采用Cochran-Armitage趋势检验评估联合治疗>CBT或氟西汀>安慰剂的假设模式。
临床怎么用
- 氟西汀可用于疑病症治疗,联合CBT可能带来少量额外获益。
- 需注意约半数患者对现有治疗无应答,应考虑新的或更强化的干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Prior studies of hypochondriasis demonstrated benefits for pharmacotherapy and for cognitive-behavioral therapy (CBT). This study examined whether joint treatment offers additional benefit. METHOD: Patients with DSM-IV hypochondriasis (N=195) were randomly assigned to one of four treatments-placebo, CBT, fluoxetine, or joint treatment with both fluoxetine and CBT. Evaluations assessed hypochondriasis, other psychopathology, adverse events, functional status, and quality of life. The primary analysis assessed outcome at week 24 among the intent-to-treat sample, with responders defined as having a 25% or greater improvement over baseline on both the Whiteley Index and a modified version of the Yale-Brown Obsessive Compulsive Scale for hypochondriasis (H-YBOCS-M). The Cochran-Armitage trend test assessed the hypothesized pattern of response: joint treatment > CBT or fluoxetine treatment > placebo treatment. RESULTS: The predicted pattern of response was statistically significant, as shown by the following responder rates: joint treatment group, 47.2%; single active treatment group, 41.8%; and placebo group, 29.6%. Responder rates for each active treatment were not significantly different from the rate for placebo. Secondary analyses of the Whiteley Index as a continuous measure revealed that, compared with placebo, fluoxetine (but not CBT) was significantly more effective at week 24 in reducing hypochondriasis and had a significantly faster rate of improvement over 24 weeks. Fluoxetine also resulted in significantly less anxiety and better quality of life than placebo. Dropout rates did not differ between groups, and treatment-emergent adverse events were evenly distributed. CONCLUSIONS: This study supports the safety, tolerance, and efficacy of fluoxetine for hypochondriasis. Joint treatment provided a small incremental benefit. Because approximately 50% of patients did not respond to the study treatments, new or more intensive approaches are needed.
引用
- Fallon BA, Ahern DK, Pavlicova M, et al. A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis. Am J Psychiatry. 2017. PMID: 28659038. doi:10.1176/appi.ajp.2017.16020189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。